Posted by Michael Wonder on 21 Apr 2022
Will the shadow of Aduhelm cloud FDA’s decision-making on an ALS therapy?
21 April 2022 - On March 30, an FDA advisory panel voted 6 to 4 against recommending approval of what might be the most effective treatment to date for amyotrophic lateral sclerosis.
The panel’s decision is not binding, and the FDA could disregard its recommendation when it issues its final decision on the treatment, called AMX0035, in June.
